ATE555788T1 - Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität - Google Patents

Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität

Info

Publication number
ATE555788T1
ATE555788T1 AT07812295T AT07812295T ATE555788T1 AT E555788 T1 ATE555788 T1 AT E555788T1 AT 07812295 T AT07812295 T AT 07812295T AT 07812295 T AT07812295 T AT 07812295T AT E555788 T1 ATE555788 T1 AT E555788T1
Authority
AT
Austria
Prior art keywords
glucocerebrosidase
enhancement
beta
neurological diseases
treating neurological
Prior art date
Application number
AT07812295T
Other languages
English (en)
Inventor
Brandon Wustman
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38834440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE555788(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of ATE555788T1 publication Critical patent/ATE555788T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AT07812295T 2006-06-23 2007-06-25 Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität ATE555788T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81595206P 2006-06-23 2006-06-23
PCT/US2007/072016 WO2007150064A2 (en) 2006-06-23 2007-06-25 METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE

Publications (1)

Publication Number Publication Date
ATE555788T1 true ATE555788T1 (de) 2012-05-15

Family

ID=38834440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07812295T ATE555788T1 (de) 2006-06-23 2007-06-25 Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität

Country Status (15)

Country Link
US (4) US7829579B2 (de)
EP (1) EP2040548B1 (de)
JP (1) JP5303458B2 (de)
KR (1) KR101402554B1 (de)
AT (1) ATE555788T1 (de)
AU (1) AU2007260812B2 (de)
BR (1) BRPI0713442A2 (de)
CA (1) CA2656643C (de)
DK (1) DK2040548T3 (de)
ES (1) ES2387845T3 (de)
IL (1) IL196151A (de)
MX (1) MX2009000032A (de)
PT (1) PT2040548E (de)
WO (1) WO2007150064A2 (de)
ZA (1) ZA200900270B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
ATE555788T1 (de) 2006-06-23 2012-05-15 Amicus Therapeutics Inc Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität
GB0622702D0 (en) * 2006-11-15 2006-12-27 Univ Dundee Selective glycosidase inhibitors
US8454954B2 (en) * 2007-05-16 2013-06-04 The Brigham And Women's Hospital, Inc. Treatment of synucleinopathies
EP2484371B1 (de) 2008-06-26 2014-12-17 Orphazyme APS Verwendung von HSP70 als Regler der enzymatischen Aktivität
CA2745451A1 (en) * 2008-11-14 2010-05-20 Parkinson's Institute Compositions and methods for the treatment of altered a-synuclein function
GB0906159D0 (en) * 2009-04-09 2009-05-20 Summit Corp Plc Drug combination for the treatment of proteostatic diseases
BRPI1010517A2 (pt) * 2009-04-09 2017-01-31 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal
CA2758187C (en) * 2009-04-09 2017-03-07 Robert Boyd Methods for preventing and/or treating degenerative disorders of the central nervous system
US9206457B2 (en) * 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
WO2010138608A1 (en) * 2009-05-26 2010-12-02 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
NZ623910A (en) * 2009-07-28 2016-06-24 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
PT2995306T (pt) * 2009-10-19 2019-03-29 Amicus Therapeutics Inc Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal
JP6061677B2 (ja) * 2009-10-19 2017-01-18 アミカス セラピューティックス インコーポレイテッド 薬理シャペロンを用いてガングリオシドの活性を増大させて、アルツハイマー病を治療するための方法
DK2490532T3 (en) * 2009-10-19 2017-02-27 Amicus Therapeutics Inc Hitherto UNKNOWN COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF DEGENERATIVE DISORDERS IN THE CENTRAL Nervous System
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
RS58718B1 (sr) 2011-05-12 2019-06-28 Proteostasis Therapeutics Inc Regulatori proteostaze
EP2533051A1 (de) * 2011-06-06 2012-12-12 Centogene GmbH Verfahren zur Diagnose von Morbus Gaucher
US9845327B2 (en) 2011-06-22 2017-12-19 The General Hospital Corporation Treatment of proteinopathies
WO2013112706A1 (en) 2012-01-25 2013-08-01 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
BR112015009746A2 (pt) * 2012-11-05 2017-08-15 Genzyme Corp Agente que aumenta atividade de glicocerebrosidase em mamíferos
WO2014089449A1 (en) 2012-12-07 2014-06-12 Rush University Nedical Center Composition and method for treating neuronal ceroid lipofuscinosis
EP3087056A4 (de) 2013-12-23 2017-07-19 Alectos Therapeutics Inc. Glucocerebrosidasemodulatoren und verwendungen davon
US9675627B2 (en) 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
CN107001379B (zh) 2014-11-06 2022-11-01 Bial研发投资股份有限公司 取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途
WO2016179497A1 (en) 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
WO2017176960A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017176962A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics, Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US10787454B2 (en) 2016-04-06 2020-09-29 BIAL—BioTech Investments, Inc. Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3442530A1 (de) 2016-04-13 2019-02-20 Orphazyme A/S Hitzeschockproteinen und cholesterinhomöostase
SI3448382T1 (sl) 2016-04-29 2021-03-31 Orphazyme A/S, c/o COBIS A/S Arimoclomol za zdravljenje motenj, povezanih z glukocerebrozidazo
MX389579B (es) 2016-05-05 2025-03-20 Bial R&D Invest S A IMIDAZO[1,2-b]PIRIDAZINAS SUSTITUIDAS, IMIDAZO[1,5-b]PIRIDAZINAS SUSTITUIDAS, COMPUESTOS RELACIONADOS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS
EP3264092A1 (de) * 2016-07-01 2018-01-03 Centogene AG Verwendung von lyso-gb1 als krankheitsassoziiertes ziel
KR20240171186A (ko) 2017-10-26 2024-12-06 다케다 야쿠힌 고교 가부시키가이샤 글루코세레브로시다제 및 이소파고민을 포함하는 제제
CN108428452B (zh) 2018-03-14 2019-12-13 百度在线网络技术（北京）有限公司 终端支架和远场语音交互系统
AU2019295765B2 (en) 2018-06-27 2024-08-29 Yumanity, Inc. Proteasome activity enhancing compounds
EP3814336A1 (de) 2018-06-27 2021-05-05 Proteostasis Therapeutics, Inc. Verbindungen zur erhöhung der proteasomaktivität
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
JP7712673B2 (ja) * 2018-12-05 2025-07-24 ワシントン・ユニバーシティ 神経の疾患を検出し、予防し、回復に向かわせ、治療する方法
EP3959196A4 (de) * 2019-04-25 2023-04-12 Takeda Pharmaceutical Company Limited Isofagominsalze, verfahren zur verwendung und formulierungen
CN111450306B (zh) * 2020-03-06 2021-11-19 大连理工大学 外用纳米羟基磷灰石/聚多巴胺湿黏附型止血粉及其制备方法
WO2022106614A1 (en) 2020-11-19 2022-05-27 Orphazyme A/S Processes for preparing arimoclomol citrate and intermediates thereof
US20240262832A1 (en) * 2021-04-30 2024-08-08 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2333362B (en) * 1996-10-15 2001-05-16 Imperial College Typing and diagnosis of spongiform encephalopathy
NZ335290A (en) * 1996-10-15 2001-08-31 D Gen Ltd Diagnosis an typing of spongiform encephalopathy (or bovine spongiform encephalopathy (BSE))
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
PT2857036T (pt) * 2003-01-31 2017-03-13 Mount Sinai School Of Medicine Of N Y Univ Terapia combinada para o tratamento de distúrbios de deficiência proteica
BRPI0416216A (pt) 2003-11-12 2006-12-26 Amicus Therapeutics Inc composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
MX2007015602A (es) 2005-06-08 2008-02-21 Amicus Therapeutics Inc Tratamiento de trastornos del sistema nervioso central asociados con mutaciones en genes que codifican las enzimas lisosomicas.
US7501439B2 (en) * 2006-05-24 2009-03-10 Amicus Therapeutics, Inc. Tartrate salt of isofagomine and methods of use
ATE555788T1 (de) 2006-06-23 2012-05-15 Amicus Therapeutics Inc Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität
ES2490143T3 (es) * 2007-05-22 2014-09-03 Amicus Therapeutics, Inc. Nuevo método para preparar isofagomina y sus derivados

Also Published As

Publication number Publication date
US9402837B2 (en) 2016-08-02
MX2009000032A (es) 2009-01-23
DK2040548T3 (da) 2012-08-13
US20080009516A1 (en) 2008-01-10
US10064851B2 (en) 2018-09-04
ZA200900270B (en) 2011-02-23
WO2007150064A3 (en) 2008-02-21
US7829579B2 (en) 2010-11-09
US20150025109A1 (en) 2015-01-22
AU2007260812B2 (en) 2012-08-16
EP2040548B1 (de) 2012-05-02
BRPI0713442A2 (pt) 2012-03-06
EP2040548A2 (de) 2009-04-01
US20110052613A1 (en) 2011-03-03
US20170027919A1 (en) 2017-02-02
US9119845B2 (en) 2015-09-01
IL196151A0 (en) 2009-11-18
JP2009541489A (ja) 2009-11-26
JP5303458B2 (ja) 2013-10-02
AU2007260812A1 (en) 2007-12-27
KR101402554B1 (ko) 2014-06-19
PT2040548E (pt) 2012-08-02
CA2656643C (en) 2015-08-25
IL196151A (en) 2015-08-31
EP2040548A4 (de) 2009-12-23
ES2387845T3 (es) 2012-10-02
CA2656643A1 (en) 2007-12-27
WO2007150064A2 (en) 2007-12-27
KR20090021393A (ko) 2009-03-03

Similar Documents

Publication Publication Date Title
ZA200900270B (en) Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase
Madhyastha et al. MicroRNA signature in diabetic wound healing: promotive role of miR‐21 in fibroblast migration
ATE516353T1 (de) Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs
MX2020011747A (es) Terapias genicas para los trastornos lisosomales.
MX2010004074A (es) Combinacion 059.
CY1108927T1 (el) Αναστολεις μιτωτικης κινεσινης
NO20050198D0 (no) Mitotiske kinesininhibitorer
BR112013020041A2 (pt) compostos e métodos para a modulação de quinases, e indicações para os mesmos
DE60324449D1 (de) Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
MX2009010557A (es) Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
Wu et al. Pressure and inflammatory stimulation induced increase of cadherin-11 is mediated by PI3K/Akt pathway in synovial fibroblasts from temporomandibular joint
EP4707400A3 (de) Gentherapien für lysosomale erkrankungen
GB201315212D0 (en) Systems, compositions and methods for transplantation
Chen et al. Botulinum toxin type A-targeted SPP1 contributes to neuropathic pain by the activation of microglia pyroptosis
GT200500215A (es) Amidas sustituidas de àcido tienopirrolcarboxìlico, amidas del àcido pirrolotiazolcarboxìlico y anàlogos relacionados como inhibidores de la epsilon caseìna quinasa i
ATE522540T1 (de) Kurze interferierende ribonukleinsäuren zur behandlung allergischer krankheiten
MX2011012596A (es) Metodos para incrementar os efectos de un inhibidor selectivo de la recaptacion de serotonina en los mamiferos.
CN105251008B (zh) MicroRNA‑155拮抗剂在制备治疗硬皮病的药物中的应用
ATE529514T1 (de) Sirna zur hemmung der il-6-expression und diese enthaltende zusammensetzung
CN103656685B (zh) microRNA-219在制备抗癫痫药物中的应用
Offen et al. Increase in autophagy and amyloid beta uptake in apoe expressing astrocytes after calpain knock down by CRISPR-Cas9
ATE554069T1 (de) Verwendung von tetrahydropyridinen zur behandlung von erkrankungen des zentralnervensystems
EA202192739A1 (ru) Генная терапия лизосомальных нарушений
EA202192737A1 (ru) Генная терапия лизосомальных нарушений